aTyr Pharma Inc. (LIFE)
aTyr Pharma Statistics
Share Statistics
aTyr Pharma has 69.01M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 69.01M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 67.12M |
| Failed to Deliver (FTD) Shares | 45.71K |
| FTD / Avg. Volume | 9.5% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.5 and the forward PE ratio is null. aTyr Pharma's PEG ratio is 0.04.
| PE Ratio | -1.5 |
| Forward PE | n/a |
| PS Ratio | 214.12 |
| Forward PS | null |
| PB Ratio | 0.83 |
| P/FCF Ratio | -2.02 |
| PEG Ratio | 0.04 |
Enterprise Valuation
aTyr Pharma has an Enterprise Value (EV) of 68.14M.
| EV / Sales | 193.02 |
| EV / EBITDA | -1.31 |
| EV / EBIT | -2.05 |
| EV / FCF | -1.82 |
Financial Position
The company has a current ratio of 6.27, with a Debt / Equity ratio of 0.17.
| Current Ratio | 6.27 |
| Quick Ratio | 11.03 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -0.29 |
| Debt / FCF | -0.4 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -55.58% and Return on Invested Capital is -51.92%.
| Return on Equity | -55.58% |
| Return on Assets | -41.28% |
| Return on Invested Capital | -51.92% |
| Revenue Per Employee | $6.3K |
| Profits Per Employee | $-899.8K |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | -0.04 |
Taxes
| Income Tax | -8K |
| Effective Tax Rate | 0.02% |
Stock Price Statistics
The stock price has increased by 15.85% in the last 52 weeks. The beta is 1.19, so aTyr Pharma's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 15.85% |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 39.57 |
| Average Volume (20 Days) | 480.98K |
Income Statement
In the last 12 months, aTyr Pharma had revenue of 353K and earned -50.39M in profits. Earnings per share was -0.94.
| Revenue | 353K |
| Gross Profit | -2.39M |
| Operating Income | -54.92M |
| Net Income | -50.39M |
| EBITDA | -52.18M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
The company has 22.54M in cash and 15.1M in debt, giving a net cash position of 7.45M.
| Cash & Cash Equivalents | 22.54M |
| Total Debt | 15.1M |
| Net Cash | 7.45M |
| Retained Earnings | -468.02M |
| Total Assets | 113.25M |
| Working Capital | 80.94M |
Cash Flow
In the last 12 months, operating cash flow was -33.22M and capital expenditures -4.21M, giving a free cash flow of -37.44M.
| Operating Cash Flow | -33.22M |
| Capital Expenditures | -4.21M |
| Free Cash Flow | -37.44M |
| FCF Per Share | -0.7 |
Margins
Gross margin is -676.49%, with operating and profit margins of -15557.79% and -14274.5%.
| Gross Margin | -676.49% |
| Operating Margin | -15557.79% |
| Pretax Margin | -14276.77% |
| Profit Margin | -14274.5% |
| EBITDA Margin | -14781.3% |
| EBIT Margin | -15557.79% |
| FCF Margin | -10605.1% |
Dividends & Yields
LIFE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -66.67% |
| FCF Yield | -49.53% |
Analyst Forecast
The average price target for LIFE is $35, which is 1742.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 1742.1% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 1, 2019. It was a backward split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -4.1 |
| Piotroski F-Score | 1 |